Does levosimendan act as a Ca²⁺ sensitizer or PDE3 inhibitor?: Commentary on Orstavik et al., Br J Pharmacol 171: 5169–5181

Linked Article

This article is a Commentary on Orstavik O, Ata SH, Riise J, Dahl CP, Andersen GO, Levy FO, Skomedal T, Osnes J‐B, and Qvigstad E (2014). PDE3‐inhibition by levosimendan is sufficient to account for its inotropic effect in failing human heart . Br J Pharmacol 171: 5169–5181. doi: 10.1111/bph.12647

DOI: 10.1111/bph.12649

View this article

• Full article (html)
• Enhanced article (html)
• PDF
• References